Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.
about
Proteinuria and baseline renal function predict mortality and renal outcomes after sirolimus therapy in liver transplantation recipients.Regulation of blood-testis barrier (BTB) dynamics during spermatogenesis via the "Yin" and "Yang" effects of mammalian target of rapamycin complex 1 (mTORC1) and mTORC2.Tacrolimus combined with low-dose corticosteroids is an effective and safe therapeutic option for refractory IgA nephropathy.Prospects for mTOR inhibitor use in patients with polycystic kidney disease and hamartomatous diseases.Toxicity spectrum of inhibitors of mammalian target of rapamycin in organ transplantation: etiology, pathogenesis and treatment.Proliferation signal inhibitors and post-transplant malignancies in heart transplantation: practical clinical management questions.Endothelial dysfunction and cardiac allograft vasculopathy.Chronic renal insufficiency in heart transplant recipients: risk factors and management options.Safety of mTOR inhibitors in adult solid organ transplantation.mTOR regulates expression of slit diaphragm proteins and cytoskeleton structure in podocytes.Belatacept for renal rescue in lung transplant patients.Conversion from calcineurin inhibitors to mTOR inhibitors stabilizes diabetic and hypertensive nephropathy after liver transplant.Nonalbumin proteinuria in islet transplant recipients.The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes.Rapamycin-induced proteinuria following allogeneic hematopoietic stem cell transplantation.Decrease in sirolimus-induced proteinuria after switch to everolimus in a liver transplant recipient with diabetic nephropathy.The role of sirolimus in proteinuria in diabetic nephropathy rats.Renal protection strategies after heart transplantation.Impact of calcineurin-inhibitor conversion to mTOR inhibitor on renal allograft function in a prednisone-free regimen.
P2860
Q33587143-5A19EB55-40B6-427E-9B7A-A4DF3498A152Q33863571-49167A01-9CBB-4AE0-8B85-63C44B6D8F7CQ37205233-8A4BA773-3C08-49CA-B6FB-2537649AAE33Q37760379-54D2E362-11A9-4585-8892-7A39AFEFFDA3Q37873950-9C8B8726-593D-4A02-988C-3A387FA683D6Q37876951-AF3A6236-646E-4EEE-A5DD-F552F8D57E01Q38058477-D9965EB2-768F-4E71-BA90-D4D92C359AE6Q38240994-EF46DCEB-63D5-4217-8CB9-5BBD2A4773A5Q38669190-3444E2C7-3437-43B3-8265-F6441590C876Q39914641-ED35B30E-3D34-4EED-ABD6-8D129725FB4AQ40201063-6428B727-1915-4BA8-B1FB-09D0720B636AQ43200374-CCF892EB-7B9D-48C3-85B8-E61B762DE738Q43251594-CB0F5059-9F3B-43C8-9334-39F647B7A5A5Q44658058-AFDDF4DA-753F-47E3-ACAF-A961E97EEF30Q46158153-6DDF6141-91EE-4312-B877-D91C8F18755BQ46224052-39BFB6C4-C037-49A4-9004-D9452A835944Q47168870-A17EC501-12A4-4930-8130-38573A183C81Q48277261-9F4848D7-CDB6-47C3-8171-02CC65747E3CQ54411021-3E091CF6-F384-4126-9F4B-7DA1F97AB343
P2860
Development of proteinuria after switch to sirolimus-based immunosuppression in long-term cardiac transplant patients.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Development of proteinuria aft ...... m cardiac transplant patients.
@en
Development of proteinuria aft ...... m cardiac transplant patients.
@nl
type
label
Development of proteinuria aft ...... m cardiac transplant patients.
@en
Development of proteinuria aft ...... m cardiac transplant patients.
@nl
prefLabel
Development of proteinuria aft ...... m cardiac transplant patients.
@en
Development of proteinuria aft ...... m cardiac transplant patients.
@nl
P2093
P2860
P1476
Development of proteinuria aft ...... rm cardiac transplant patients
@en
P2093
A O Zuckermann
A Z Aliabadi
D Kammerstätter
G Seebacher
P2860
P304
P356
10.1111/J.1600-6143.2007.02142.X
P407
P577
2008-02-05T00:00:00Z